Editorial
doi: 10.1016/j.eururo.2008.02.047.
Epub 2008 Mar 11.
Editorial comment on: Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam)
- PMID: 18353530
- DOI: 10.1016/j.eururo.2008.02.047
Item in Clipboard
Editorial
Editorial comment on: Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam)
Eur Urol.
2009 Feb.
No abstract available
Comment on
-
Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).Eur Urol. 2009 Feb;55(2):385-92. doi: 10.1016/j.eururo.2008.02.046. Epub 2008 Mar 11. Eur Urol. 2009. PMID: 18353529 Clinical Trial.
Similar articles
-
Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer.J Urol. 2011 Mar;185(3):828-32. doi: 10.1016/j.juro.2010.10.079. Epub 2011 Jan 15. J Urol. 2011. PMID: 21239021
-
Rural residence and prostate cancer screening with prostate-specific antigen.Rural Remote Health. 2009 Apr-Jun;9(2):1227. Epub 2009 Jun 18. Rural Remote Health. 2009. PMID: 19594290
-
Screening for prostate cancer.J Fam Pract. 1999 Aug;48(8):581-2. J Fam Pract. 1999. PMID: 10496634 No abstract available.
-
Randomized trial results did not resolve controversies surrounding prostate cancer screening.Curr Opin Urol. 2010 May;20(3):189-93. doi: 10.1097/MOU.0b013e3283383b55. Curr Opin Urol. 2010. PMID: 20224414 Review.
-
Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer.Curr Opin Urol. 2009 May;19(3):227-31. doi: 10.1097/MOU.0b013e328329a2d0. Curr Opin Urol. 2009. PMID: 19357513 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
